Illumina (ILMN) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.57 per share a year ago. These figures are adjusted for non-recurring items.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2023.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its third quarter of fiscal 2023, which ended June 30, 2023.
Siemens Healthineers AG today announces its results for the third quarter, ending June 30, of fiscal year 2023.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2023.
Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended July 2, 2023.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended July 1, 2023.
Quest Diagnostics on Wednesday reported that its second quarter revenues fell 5 percent year over year although its base business revenues increased nearly 10 percent. The company also beat analysts' expectations on the top and bottom lines.
Mindray is expected to achieve the operating income of 14.855 billion yuan to 16.093 billion yuan in the first three quarters of 2020, a year-on-year growth of 20% to 30%; Kehua announced that the company expects the net profit of the first
✔ All (79)
✔ Press release (0)
✔ Industry news (79)
Don’t miss important updates about the show and the in vitro diagnostic industry.
Sign-up for our newsletter today.
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.